

## Investor Statement Access to Medicine Index

The goal of investors is to create long-term shareholder value in the companies in which they invest. This potential is maximized by investing in well-managed, high quality companies, where the management team have considered fully the range of business risks and opportunities facing their companies, and taken appropriate action to manage these. Alongside assessment of traditional financial risks and opportunities, there is growing recognition among the investment community of the potential for environmental, social and governance (ESG) factors to impact the financial performance of companies. As such, investors are also seeking for companies to demonstrate effective management of ESG factors.

We believe the issue of access to medicine in developing countries can present potentially significant business impacts for global companies in the pharmaceutical sector. As greater emphasis is placed on accessing new markets as a source for future industry growth, pharmaceutical companies are brought into ever closer contact with access to medicine issues in developing countries. Mismanagement of these issues can impact negatively on political relationships and corporate brands and encumber market access. On the other hand, if pharmaceutical companies act responsibly and with foresight, commercial potential can be unlocked.

As investors, we seek assurances that the management of the companies in which we invest have fully considered the risks and opportunities of this issue, and have effective policies and processes for dealing with the challenges. By taking management of this issue into account, alongside other key ESG and financial issues, the investment community can better assess the long-term investment value of such companies. We are increasingly reviewing corporate approaches to access to medicine and associated aspects of intellectual property as a key strategic consideration in our analysis of the sector, where this is appropriate to do so.

It is in this context that the investors listed below welcome the development of analytical tools such as the Access to Medicine Index, which may be used by investors to assess companies' management of the issue, based on information obtained from their reporting activities.

By our explicit inclusion in this statement, we are agreed on the following:

- We believe the issue of access to medicine is potentially material to long-term shareholder value creation, and is a potentially relevant consideration when forming views on the strategic positioning of companies in the pharmaceutical sector. We welcome the Access to Medicine Foundation's efforts to develop a credible, transparent and independent tool, which could be useful with regards to specific issue:
- We consider that pharmaceutical companies have an important role to play in addressing the access to medicine issue;
- We will review and take into account the analysis generated from the Index as appropriate in the ESG analysis we conduct on the companies we invest in;
- We hope that the Index will contribute towards creating greater awareness within the industry of this important issue, and act as a tool for highlighting leadership and good practice, as well as gaps and challenges;
- We will provide investor input into the evolution of the Index to ensure it considers the investment perspective as appropriate and remains dynamic and relevant to the debate.

We would encourage other investors to join us in this statement.

## SIGNATORY INVESTORS





## TOTAL ASSETS UNDER MANAGEMENT IN EXCESS OF USD 22 TRILLION

For more information please contact Avanti Gupta agupta@accesstomedicinefoundation.org



## **CONTACTS**

Investor	Signatory Contact	Investor	Signatory Contact
Aberdeen Investments	Nancy Hardie	Jennison Associates LLC	Linda Galsim
	Jeroen Wiercx	JLens Investment Network	Rabbi Joshua Ratner
	Donna Meyer	Joh. Berenberg, Gossler & Co. KG (Berenberg)	Dr. Rupini Rajagopalan
0	Heike Cosse	Kempen Capital Management	Eszter Vitorino
•	Arnaud Celka	Kieger AG	Panagiota Balfousia
, ,	Tom Allen	LBP AM	Luisa Florez
	Peter Loow	La Financiere de l'Echiquier	Coline Pavot
	Saskia Kort-Chick Katrin Wohlwend	Länsförsäkringar AB Legal & General Investment Management	Kristofer Dreiman Maria Larsson Ortino
	Guillaume Mascotto	Local Government Super	Moya Yip
	Caroline Le Meaux	M&G Investments	Ben Constable Maxwell
	Els Knoope	Mercy Investment Services	Donna Meyer
-	Fiona Manning	Miller/Howard Investments	Luan Steinhilber
	Piet Sprengers	Mirova	Manon Salomez
	Jack Julicher	Mitsubishi UFJ Trust and Banking Corporation	Masahiro Kato
	Toru Terasawa	MN	Louis Kranenburg
	Jacques Chatain	Natixis	Marina Iodice
Australian Ethical Investment	Stuart Palmer	NEIInvestments	Jamie Bonham
Aviva Investors	Steve Waygood	Ninety One	Stephanie Niven
AXA Investment Managers	Gilles Moec	NN Investment Partners	Adrie Heinsbroek
	Stefano Giuliani	Nomura Asset Management	Toshiyuki Imamura
	Helena Vines Fiestas	Nordea Asset Management	Magdalena Kettis
	Donna Meyer	Northwest Coalition for Responsible Investment	Timnit Ghermay
	Lauren Compere	Ofi Invest Asset Management	Eric Van La Beck
	Stuart Dalheim	Öhman	Fredric Nystrom
·	Sophie Deleuze	Parnassus Investments	Benjamin Allen
	Marie Payne	Pensioenfonds Medewerkers Apotheken (PMA)	Remco Velasquez
	Mark Elliot	PGGM PGIM Fixed Income	Rogier Snijdewind Birgit Lundem Jakobsen
	Amy Browne Christophe Borysiewicz	Poste Vita S.p.A.	Antonio Colombi
	Sara Nordbrand	Quaestio Capital SGR Spa	Mario Baronci
	Marshall Gordon	Radicant Bank AG	Eve Morelli
	Ayo Olatunji	RAM Active Investments SA	Cyrille Joye
	Nimrit Kang	Redwheel	Chris Anker
	Catherine McCabe	Reynders, McVeigh Capital Management, LLC	Maria Egan
Cometa Pension Fund	Maurizio Agazzi	Robeco	Peter van der Werf
Comgest	Sebastien Thevoux-Chabuel	Royal London Asset Management	Ashley Hamilton Claxton
Coöperatie VGZ UA	Erik Jan van Bergen	Schroders	Seema Suchak
C-QUADRAT Asset Management GmbH	Günther Kastner	SEB Asset Management	Anette Andersson
Crédit Mutuel Asset Management	Isabelle Delattre	SPH	Bram Stageman
	Yvo Boon	SPMS	Marcel Roberts
	Ann Roberts	Stewart Investors Stewart Investors	Jennifer Stephen
	Donna Meyer	Stichting Algemeen Pensioenfonds Unilever	Willy Westerborg
	Rosanne Lissow	Nederland	C-::: K
	Donna Meyer	Sumitomo Mitsui Trust Asset Management Co., Ltd. Swedbank Robur Fonder AB	
	Lise Børresen	Sycomore Asset Management	Pia Gisgård Bertille Knuckey
	Carole Laible	T. Rowe Price	Maria Elena Drew
	Roz Yazdan Francois Lett	The Congregation of St. Joseph	Donna Meyer
	Ketan Patel	The Dai-ichi Life Insurance Company, Limited	Hiroko Ishii
Edmond de Rothschild Asset Management (France)		The Sisters of St. Francis of Philadelphia	Nora Nash
	Stefano Montobbio	The Socially Responsible Investing Group of 1919	Alison Bevilacqua
	Jérôme Tendeau	Investment Counsel	
	Ellie Higgins	The Sustainability Group of Loring, Wolcott &	Larisa Ruoff
	Christophe Borysiewicz	Coolidge	
- ·	Lousiana Salge	Tokio Marine Asset Management Co., Ltd.	Yo Mizuno
	Vincent Kaufmann	Trillium Asset Management, LLC.	Jonas Kron
	Luca Mattiazzi	Trinity Health	Cathy Rowan
Fondita Fund Management Company	Janna Haahtela	Triodos Investment Management	Erik Breen
	Doris Hauser	Trusteam Finance	Claire Berthier
	Mark Harland	Unigestion	Eric Cockshutt
	Matt Crossman	Union Investment United Church Funds	Dr. Henrik Pontzen Noah Tabor
- '	Jana Celeste	USS USS	Daniel Summerfield
	Luc Deschamps	Valori Asset Management	Giancarlo Fragomeno
	Aurelien Bon	Vancity Investment Management	Kelly Hirsch
	Jo-Annie Pinto	Varma Mutual Pension Insurance Company	Kaisa Ojainmaa
	Christine Chow,	Vontobel	Natalia Ernst
	Miriam Fernández Jiménez	VvAA Groep B.V.	Christel de Groot
	Meg Jones-Monteiro	VvAA Schadeverzekeringen N.V.	Christel de Groot
Impax Asset Management and Pax World Funds	Evie Paterson Mats Lagerqvist	Wesleyan Group	Milly Mcloughlin
Indocan			
		WHEB Asset Management	Seb Beloe
J. Safra Sarasin	Jullia Wittenberg Antony Marsden	WHEB Asset Management Zevin Asset Management	Seb Beloe Pat Miguel Tomaino